Royal London Asset Management Ltd. Reduces Position in Stryker Corporation $SYK

by · The Markets Daily

Royal London Asset Management Ltd. trimmed its holdings in Stryker Corporation (NYSE:SYK – Free Report) by 1.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 340,466 shares of the medical technology company’s stock after selling 3,684 shares during the quarter. Royal London Asset Management Ltd. owned approximately 0.09% of Stryker worth $107,192,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of SYK. Mufg Securities Americas Inc. grew its holdings in shares of Stryker by 9.0% in the second quarter. Mufg Securities Americas Inc. now owns 10,392 shares of the medical technology company’s stock worth $3,272,000 after purchasing an additional 862 shares during the last quarter. Van ECK Associates Corp lifted its holdings in Stryker by 7.6% during the 2nd quarter. Van ECK Associates Corp now owns 22,011 shares of the medical technology company’s stock valued at $6,930,000 after buying an additional 1,555 shares in the last quarter. Ferguson Wellman Capital Management Inc. boosted its position in Stryker by 1.2% in the 2nd quarter. Ferguson Wellman Capital Management Inc. now owns 186,935 shares of the medical technology company’s stock valued at $58,855,000 after buying an additional 2,180 shares during the period. Roffman Miller Associates Inc. PA increased its position in shares of Stryker by 1.0% during the second quarter. Roffman Miller Associates Inc. PA now owns 127,268 shares of the medical technology company’s stock worth $40,069,000 after acquiring an additional 1,246 shares during the period. Finally, Nissay Asset Management Corp Japan raised its stake in shares of Stryker by 2.5% during the second quarter. Nissay Asset Management Corp Japan now owns 51,065 shares of the medical technology company’s stock valued at $16,077,000 after acquiring an additional 1,262 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 50,000 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the sale, the director owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Dylan Bram Crotty sold 441 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the transaction, the insider directly owned 6,102 shares in the company, valued at $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 351,267 shares of company stock valued at $118,197,701. Insiders own 4.60% of the company’s stock.

Stryker Trading Up 2.9%

SYK opened at $331.32 on Friday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The stock has a fifty day moving average price of $329.10 and a 200-day moving average price of $331.47. The firm has a market cap of $127.08 billion, a price-to-earnings ratio of 34.33, a PEG ratio of 2.05 and a beta of 0.76. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK – Get Free Report) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm’s revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the company posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 36.48%.

Wall Street Analyst Weigh In

SYK has been the subject of a number of research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Stryker in a report on Friday, July 31st. BMO Capital Markets began coverage on Stryker in a research report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price target on the stock. The Goldman Sachs Group restated a “neutral” rating and set a $361.00 price target on shares of Stryker in a research note on Friday, May 1st. Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a research note on Friday, May 1st. Finally, UBS Group started coverage on shares of Stryker in a report on Tuesday, July 28th. They set a “buy” rating and a $400.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

Get Our Latest Analysis on SYK

About Stryker

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Further Reading